Inflammatory bowel disease: long-term therapeutic challenges

Area of Science:

• Gastroenterology and Immunology
• Pharmacogenomics
• Pediatric Inflammatory Bowel Disease

Background:

• Long-term remission is the primary goal of inflammatory bowel disease (IBD) treatment.
• Patients often lose response to therapy or develop complications, necessitating treatment cessation.
• Factors influencing treatment response include medication properties and host-related influences.

Purpose of the Study:

• To review the long-term outcomes of IBD, particularly in pediatric-onset cases.
• To discuss factors contributing to the loss of treatment response in IBD.
• To explore the future of personalized therapy for improving IBD outcomes.

Main Methods:

• Literature review focusing on IBD long-term outcomes and treatment response.
• Discussion of etiological factors, including molecular causes and pharmacogenomics.
• Exploration of emerging personalized therapeutic strategies.

Main Results:

• Loss of treatment response and complications are significant challenges in IBD management.
• Individual etiological factors and pharmacogenomic influences impact long-term outcomes.
• Novel medications targeting new pathways are emerging.

Conclusions:

• Personalized therapeutic management integrating biological and multiomic data is the future of IBD treatment.
• Predicting disease outcomes through multiomic data integration will enhance patient care.
• Translational research is paving the way for advanced IBD therapies.